Patents by Inventor Holia Hatoum-Makdad

Holia Hatoum-Makdad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aryl ureas with angiogenisis inhibiting activity
    Patent number: 10653684
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: May 19, 2020
    Assignee: Bayer Healthcare LLC
    Inventors: Jacques Dumas, William J. Scott, James Elting, Holia Hatoum-Makdad
  • ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY
    Publication number: 20180296541
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Application
    Filed: July 18, 2014
    Publication date: October 18, 2018
    Applicant: Bayer Healthcare LLC
    Inventors: Jacques Dumas, William Scott, James Elting, Holia Hatoum-Makdad
  • ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY
    Publication number: 20160015697
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Application
    Filed: July 18, 2014
    Publication date: January 21, 2016
    Applicant: Bayer Healthcare LLC
    Inventors: Jacques Dumas, William Scott, James Elting, Holia Hatoum-Makdad
  • Aryl ureas with angiogenesis inhibiting activity
    Patent number: 8618141
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: December 31, 2013
    Assignee: Bayer Healthcare LLC
    Inventors: Jacques Dumas, William J. Scott, James Elting, Holia Hatoum-Makdad
  • ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY
    Publication number: 20120289552
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Application
    Filed: July 18, 2012
    Publication date: November 15, 2012
    Applicant: BAYER HEALTHCARE LLC
    Inventors: Jacques DUMAS, William J. SCOTT, James ELTING, Holia HATOUM-MAKDAD
  • Aryl ureas with angiogenisis inhibiting activity
    Patent number: 8242147
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: August 14, 2012
    Assignee: Bayer Healthcare LLC
    Inventors: Jacques Dumas, William J. Scott, James Elting, Holia Hatoum-Makdad
  • ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY
    Publication number: 20110015195
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Application
    Filed: September 23, 2010
    Publication date: January 20, 2011
    Inventors: Jacques Dumas, William J. Scott, James Elting, Holia Hatoum-Makdad
  • Aryl ureas with angiogenesis inhibiting activity
    Patent number: 7838541
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Grant
    Filed: February 11, 2003
    Date of Patent: November 23, 2010
    Assignee: Bayer Healthcare, LLC
    Inventors: Jacques Dumas, William J. Scott, James Elting, Holia Hatoum-Makdad
  • Aryl Ureas With Angiogenisis Inhibiting Activity
    Publication number: 20080227828
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Application
    Filed: October 31, 2007
    Publication date: September 18, 2008
    Inventors: Jacques Dumas, William J. Scott, James Elting, Holia Hatoum-Makdad
  • Aryl ureas with raf kinase and angiogenisis inhibiting activity
    Publication number: 20040023961
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by raf kinase and diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Application
    Filed: February 11, 2003
    Publication date: February 5, 2004
    Applicant: BAYER CORPORATION
    Inventors: Jacques Dumas, William J. Scott, James Elting, Holia Hatoum-Makdad
  • Aryl ureas with angiogenisis inhibiting activity
    Publication number: 20030207870
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Application
    Filed: February 11, 2003
    Publication date: November 6, 2003
    Applicant: BAYER CORPORATION
    Inventors: Jacques Dumas, William J. Scott, James Elting, Holia Hatoum-Makdad